Fletcher-Flora Health Care Systems, Inc. Announces Master Alliance and Licensing Agreement to Utilize and Market Skeva Technologies, Inc. Web-based Outreach Software
Fletcher-Flora Health Care Systems, Inc. (OTC PINK: FFLH) announced today they have signed a Master Alliance and Licensing Agreement with Skeva Technologies, Inc. which establishes a preferred relationship and grants Fletcher-Flora exclusive rights to use and market Skeva’s Web-based outreach software in the LIS marketplace. In addition, Fletcher-Flora has signed a Letter of Intent (LOI) to purchase the Skeva software and Intellectual property.
Anaheim, CA (PRWEB) November 10, 2005
Fletcher-Flora Health Care Systems, Inc. (OTC PINK: FFLH) announced today they have signed a Master Alliance and Licensing Agreement with Skeva Technologies, Inc. which establishes a preferred relationship and grants Fletcher-Flora exclusive rights to use and market Skeva’s Web-based outreach software in the LIS marketplace. In addition, Fletcher-Flora has signed a Letter of Intent (LOI) to purchase the Skeva software and Intellectual property.
The newly acquired software capabilities will perfectly complement Fletcher-Flora’s encaLaber, a leading-edge, Web-based laboratory information system (LIS) which serves mid-to-large sized hospitals and reference laboratories, as well as its LabPak product line which is a leader in the physician office laboratory market.
The combined capabilities of encaLaber and the new Web-based outreach software will allow Fletcher-Flora’s clients to maximize their investment in equipment, information systems and people to produce additional revenues from beyond their hospital doors. This new solution is 100 percent Web-based and is HIPAA compliant. It provides a baseline electronic health record (EHR) for storing results and has interoperability with practice management systems.
“The addition of this new software package to encaLaber brings Fletcher-Flora the opportunity to better serve our client base by providing them with complete outreach capabilities that are totally integrated with our LIS,” explained Neal Flora, President and CEO of Fletcher-Flora Healthcare Systems. “We see a great opportunity to scale these capabilities down to meet the needs of our physician office-sized customers and up to serve the needs of large hospitals, reference labs and IDNs.”
“The Skeva -- Fletcher-Flora partnership will allow us to work together to explore the expanding role of laboratory outreach solutions in both the non-hospital and hospital markets. With Fletcher-Flora’s solid customer base and strong leadership, the makings of a great alliance are in place,” said Joe Rosario, President and CEO of Skeva Technologies, Inc.
The encaLaber and LabPak LIS are robust systems built on more than thirty years of experience in the physician, clinical reference and hospital laboratory markets. The basic systems include key modules for the laboratory including patient admission and demographics, order entry, specimen handling, patient inquiry, quality control, microbiology, instrument and third-party interface monitoring in real-time, multiple means of data entry, comprehensive management, patient reporting and powerful administrative tools.
EncaLaber is built to work on both Linux and Microsoft operating systems and support a selection of database engines including Unify, Microsoft MS SQL and Oracle. Its thin client design supports a more scalable, portable and accessible application with a Web-based reporting and ordering system that can either be used as part of the total LIS system or as a stand-alone accessory to any other LIS.
Each encaLaber customer has the ability to set up interpretive reporting, reflexive ordering and calculations and print advanced beneficiary notification for Medicare patients. All Fletcher-Flora products comply with COLA, CLIA and HIPAA requirements. encaLaber also lends itself well to wireless environments, which can bring real-time clinical results to physicians’ fingertips in almost any clinical environment.
About Skeva Technologies, Inc.
Skeva Technologies, Inc. is a privately held company based in the San Francisco bay area. The company was founded in 1995 and incorporated in 1996. In 1998, Skeva developed the largest secured healthcare website in the United States which was selected by Time Magazine as the “Best” in its class. Since its beginning, Skeva has been an important partner in providing clinical software solutions and consulting services to leading healthcare providers throughout the United States.
About Fletcher-Flora
For more than 20 years, Fletcher Flora Healthcare Systems, Inc., (OTC: PINK FFLH) has developed and marketed Laboratory Information Systems for physician offices, group practices and hospital laboratories. The company has grown to become a leader in both the non-hospital market and hospital market. With its LabPak® line of products, Fletcher-Flora has successfully installed more than 1,200 systems in physician office laboratories, group practices, clinics and small hospitals. For more information about encaLaber, please contact Brian Mattson at (818) 865-1716 or email bmattson@labpak. com. For further information regarding the LabPak® line of products, please contact Ken Mitchell at (877)389-9309 or email ken@labpak. com.
Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on Fletcher-Flora Healthcare Systems’ expectations and are subject to a number of risks and uncertainties beyond Fletcher-Flora's control, including, but not limited to, economic, competitive and other factors affecting Fletcher-Flora's operations, management team effectiveness, expansion strategies, available financing, market prices and recovery costs, government regulations involving Fletcher-Flora and facts and events not known at the time of this release. These statements are not guarantees of future performance, and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
# # #
